Table 5.

Summary of the number of adverse events for each treatment regimen and a description of those occurring in more than one person. Eight subjects were randomised to receive each treatment regimen, except those marked with * which contained nine subjects. † The number of subjects reporting at least one adverse event.

			Adverse events
Treatment regimen	Dose	Number of subjects†	Total number of events	Most common events (number of subjects reporting each events)
A	800 mg twice daily SQV-SGC	5	19	Headache (2); sore throats (2); increased sweating (2)
B	400 mg twice daily ritonavir	7	35	Non-specific oral hypoaesthesia (5); headache (5); nausea (3); tongue hypoaesthesia (3); taste disturbance (2); rhinitis (2)
C*	400:400 mg ritonavir:SQV-SGC	9	83	Non-specific oral hypoaesthesia (7); headache (4); nausea (2); tongue hypoaesthesia (8); taste disturbance (2); paraesthesia (2); loose stools (3); dry mouth (4); dry throat (3); abdominal upper pain (2); sore throat (3); cough (2); pruritus (3); back pain (2); dysuria (2)
D	300:600 mg ritonavir:SQV-SGC	7	57	Non-specific oral hypoaesthesia (4); headache (3); nausea (4); taste disturbance (4); paraesthesia (2); dizziness excluding vertigo (3); sore throat (3); myalgia (2); muscle cramps (2)
E	200:800 mg ritonavir:SQV-SGC	5	17	Headache (2); constipation (2)
F	300:800 mg ritonavir:SQV-SGC	7	37	Non-specific oral hypoaesthesia (5); headache (2); nausea (4); tongue hypoaesthesia (2); weakness (2); paraesthesia circumoral (2); sore throat (2)
G*	400:800 mg ritonavir:SQV-SGC	7	57	Non-specific oral hypoaesthesia (5); headache (4); nausea (6); taste disturbance (4); dizziness excluding vertigo (2); weakness (2); vomiting (2); feeling hot (2); pyrexia (2); sore throat (2); cough (2)
H	400:600 mg ritonavir:SQV-SGC	8	50	Non-specific oral hypoaesthesia (6); headache (2); nausea (3); tongue hypoaesthesia (3); taste disturbance (3); oral paraesthesia (3); dizziness excluding vertigo (3); feeling hot (2); sore throat (2)